SILVERBACK THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of SBTX and Encourages Investors to Contact the Firm
News provided byBragar Eagel & Squire
Jul 22, 2022, 10:14 PM ET
NEW YORK, July 22, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Silverback Therapeutics, Inc. (NASDAQ: SBTX) (“Silverback”) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by ARS Pharmaceuticals, Inc. (“ARS”).
Click here to learn more and participate in the action.
On July 21, 2022, Silverback announced that it had entered into an agreement to be acquired by ARS in an all-cash deal valued at $265M. Pursuant to the merger agreement, Silverback equity holders are expected to own approximately 37% of the combined company. The deal is scheduled to close in the fourth quarter of 2022.
Bragar Eagel & Squire is concerned that Silverback’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Silverback’s stockholders.
If you own shares of Silverback and are concerned about the proposed merger, or you are interested in learning more about the investigation or your legal rights and remedies, please contact Melissa Fortunato by email at email@example.com or telephone at (646) 860-9157, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.